Use of FDG PET in staging, restaging, and assessment of therapy response in ewing sarcoma

Radiographics

Volumn 29, Issue 5, 2009, Pages 1487-1500

  Bestic, Joseph M ^a   Peterson, Jeffrey J ^a   Bancroft, Laura W ^a,b  

^a MAYO CLINIC   (United States)

^b FLORIDA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADOLESCENT; ADULT; BONE TUMOR; CANCER STAGING; EWING SARCOMA; FEMALE; HUMAN; MALE; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SCINTISCANNING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; SARCOMA, EWING'S; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349905413     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.295095024     Document Type: Article

References (21)

1. Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 2008; 20(4):412-418.
2. Gerth HU, Juergens KU, Dirksen U, Gerss J, Schober O, Franzius C. Significant benefit of multi- modal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tu- mors. J Nucl Med 2007;48(12):1932-1939
3. McCarville MB, Christie R, Daw NC, Spunt SL, Kaste SC. PET/CT in the evaluation of childhood sarcomas. AJR Am J Roentgenol 2005;184(4): 1293-1304.
4. Brenner W, Bohuslavizki KH, Eary JF. PET imaging of osteosarcoma. J Nucl Med 2003;44(6):930-942
5. Eary JF, Conrad EU, Bruckner JD, et al. Quantitative [F-18] fluorodeoxyglucose positron emission to- mography in pretreatment and grading of sarcoma. Clin Cancer Res 1998;4(5):1215-1220.
6. Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med 2000;25 (11):874-881.
7. Aoki J, Watanabe H, Shinozaki T, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001;219(3):774-777.
8. Hawkins DS, Rajendran JG, Conrad EU 3rd, Bruckner JD, Eary JF. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-flu-orodeoxy-D-glucose positron emission tomography. Cancer 2002;94(12):3277-3284. [Published correction appears in Cancer 2003;97(12):3130
9. Furth C, Amthauer H, Denecke T, Ruf J, Henze G, Gutberlet M. Impact of whole-body MRI and FDG-PET on staging and assessment of therapy response in a patient with Ewing sarcoma. Pediatr Blood Cancer 2006;47(5):607-611.
10. Franzius C, Daldrup-Link HE, Sciuk J, et al. FDG- PET for detection of pulmonary metastases from malignant primary bone tumors: comparison with spiral CT. Ann Oncol 2001;12(4):479-486
11. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging 2002;29(9):1149-1154.
12. Völker T, Denecke T, Steffen I, et al. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial. J Clin Oncol 2007;25(34):5435-5441.
13. Kneisl JS, Patt JC, Johnson JC, Zuger JH. Is PET useful in detecting occult nonpulmonary metastases in pediatric bone sarcomas? Clin Orthop Relat Res 2006;450:101-104.
14. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177(1):229-236.
15. Mayer D, Bednarczyk EM. Interaction of colony-stimulating factors and fluorodeoxyglucose f(18) positron emission tomography. Ann Pharmacother 2002;36(11):1796-1799.
16. Bredella MA, Caputo GR, Steinbach LS. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. AJR Am J Roentgenol 2002;179(5):1145-1150.
17. Hawkins DS, Schuetze SM, Butrynski JE, et al. [18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23(34):8828-8834.
18. Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol 2004;34(8): 595-605.
19. Franzius C, Daldrup-Link HE, Wagner-Bohn A, et al. FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging. Ann Oncol 2002;13(1):157-160
20. Arush MW, Israel O, Postovsky S, et al. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sar- coma. Pediatr Blood Cancer 2007;49(7):901-905
21. Goodin GS, Shulkin BL, Kaufman RA, McCarville MB. PET/CT characterization of fibroosseous defects in children: 18F-FDG uptake can mimic metastatic disease. AJR Am J Roentgenol 2006;187(4): 1124-1128. [Published correction appears in AJR Am J Roentgenol 2006;187(5):1146.]